Trial shows cancer treatment could shrink tumours in patients with difficult-to-treat and aggressive cancers
A new clinical trial has demonstrated that a triple therapy combining amivantamab, pembrolizumab, and chemotherapy can significantly shrink tumors in patients with aggressive, HPV-unrelated head and neck cancers. The treatment showed a 77% success rate in tumor reduction, offering a potential breakthrough for difficult-to-treat cases.
Why it matters
This development represents a significant advancement in oncology, potentially transforming the standard of care for patients with limited treatment options.
Researchers involved in the study said the treatment could ‘transform outcomes’
Bookmark Comments Go to comments Bookmark popover Removed from bookmarks
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today.
A trial has shown a new triple therapy may help to shrink tumours in patients with difficult-to-treat and aggressive cancers.
Researchers involved in the study said the treatment regime has the potential to "transform outcomes" for those living with a specific type of head and neck cancer.
One participant, a 29-year-old mother of three diagnosed with incurable tongue cancer, said the therapy gave her renewed hope after shrinking her disease by 60 per cent.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in